Patients whose LVEF deteriorated from normal to midrange levels had a significantly higher risk of adverse clinical outcomes compared to those whose LVEF had improved from lower values.

This cross-trial analysis estimated that comprehensive disease-modifying pharmacological therapy in HFrEF patients reduces the hazard of CV death or hospital admission, compared with conventional therapy.

A diagnostic model based on symptoms partly uncovered unrecognized AF, HF and CAD in participants from the Lifelines cohort study. This resulted in the development of an 11-item questionnaire for proactive screening.

A diagnostic model with data from the Lifelines cohort study improved early detection of unrecognized AF, HF and CAD in primary care. This translated into the development of a patient questionnaire.

Omecamtiv mecarbil, a cardiac myosin activator or cardiac myotrope, has been granted Fast Track designation by the FDA for treatment of HFrEF patients.

This study showed that a SBP of 120 to 129 mmHg was associated with the lowest risk of adverse outcomes in HFpEF. SBP lowering does not explain the treatment effects of sacubitril/valsartan.

The FDA approved dapagliflozin for treatment of heart failure patients with reduced ejection fraction to reduce CV death and hospitalization for HF.

ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.

ACC 2020 The VICTORIA trial demonstrated that therapy with the sGC stimulator vericiguat reduced the primary endpoint in HFrEF patients with worsening HF condition compared to placebo.

This prospective registry study of a real-world cohort of elderly HFrEF patients showed that sacubitril/valsartan was safe and effective, even in those >80 years.

AHA 2019 A prespecified analysis of PARADIGM-HF and PARAGON-HF data allowed assessment of the effect of sacubitril/valsartan across the spectrum of ejection fractions.

AHA 2019 As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critically considers the results to get physiological clues on who should be treated and who may not benefit of ARNI therapy.